Toyofumi Chen-Yoshikawa

Prof. Toyofumi Chen-Yoshikawa

Department of Thoracic Surgery, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2021 in Cells
Verified
Journal Article
Open access
PDF file
TCToyofumi Chen-Yoshikawa
Toyofumi Chen-Yoshikawa
Lung transplantation has been established worldwide as the last treatment for end-stage respiratory failure. However, ischemia–reperfusion injury (IRI) inevitably occurs after lung transplantation. The most severe form of IRI leads to primary graft failure, which is an important cause of morbidity and mortality after lung transplantation. IRI may also induce rejection, which is the main cause of mortality in recipients. Despite advances in donor management and graft preservation, most donor grafts are still unsuitable for transplantation. Although the pulmonary endothelium is the primary target site of IRI, the pathophysiology of lung IRI remains incompletely understood. It is essential to understand the mechanism of pulmonary IRI to improve the outcomes of lung transplantation. Therefore, we reviewed the state-of-the-art in the management of pulmonary IRI after lung transplantation. Recently, the ex vivo lung perfusion (EVLP) system has been clinically introduced worldwide. Various promising therapeutic strategies for the protection of the endothelium against IRI, including EVLP, inhalation therapy with therapeutic gases and substances, fibrinolytic treatment, and mesenchymal stromal cell therapy, are awaiting clinical application. We herein review the latest advances in the field of pulmonary IRI in lung transplantation.

20 April 2020 in Cells
Verified
Journal Article
Open access
PDF file
YNYuko Nishinaga
Yuko Nishinaga
Kazuhide SatoKazuhide Sato
Kazuhide Sato
HYHirotoshi Yasui
Hirotoshi Yasui
STShunichi Taki
Shunichi Taki
KTKazuomi Takahashi
Kazuomi Takahashi
YHYoshinori Hasegawa
Yoshinori Hasegawa
Malignant pleural mesothelioma (MPM) has extremely limited treatment despite a poor prognosis. Moreover, molecular targeted therapy for MPM has not yet been implemented; thus, a new targeted therapy is highly desirable. Near-infrared photoimmunotherapy (NIR-PIT) is a recently developed cancer therapy that combines the specificity of antibodies for targeting tumors with toxicity induced by the photoabsorber after exposure to NIR-light. In this study, we developed a new phototherapy targeting podoplanin (PDPN) for MPM with the use of both NIR-PIT and an anti-PDPN antibody, NZ-1. An antibody–photosensitizer conjugate consisting of NZ-1 and phthalocyanine dye was synthesized. In vitro NIR-PIT-induced cytotoxicity was measured with both dead cell staining and luciferase activity on various MPM cell lines. In vivo NIR-PIT was examined in both the flank tumor and orthotopic mouse model with in vivo real-time imaging. In vitro NIR-PIT-induced cytotoxicity was NIR-light dose dependent. In vivo NIR-PIT led to significant reduction in both tumor volume and luciferase activity in a flank model (p < 0.05, NIR-PIT group versus NZ-1-IR700 group). The PDPN-targeted NIR-PIT resulted in a significant antitumor effect in an MPM orthotopic mouse model (p < 0.05, NIR-PIT group versus NZ-1-IR700 group). This study suggests that PDPN-targeted NIR-PIT could be a new promising treatment for MPM.

30 August 2018 in Respiratory Research
Verified
Journal Article
Open access
PDF file
KTKiminobu Tanizawa
Kiminobu Tanizawa
THTomohiro Handa
Tomohiro Handa
TKTakeshi Kubo
Takeshi Kubo
TCToyofumi Chen-Yoshikawa
Toyofumi Chen-Yoshikawa
AAAkihiro Aoyama
Akihiro Aoyama
HDHiroshi Date
Hiroshi Date
Radiological pleuroparenchymal fibroelastosis (PPFE) lesion is characterized by pleural thickening with associated signs of subpleural fibrosis on high-resolution computed tomography (HRCT). This study evaluated the clinical significance of radiological PPFE as an isolated finding or associated with other interstitial lung diseases (ILDs) in patients having fibrotic ILDs and registered for cadaveric lung transplantation (LT). This retrospective study included 118 fibrotic ILD patients registered for LT. Radiological PPFE on HRCT was assessed. The impact of radiological PPFE on clinical features and transplantation-censored survival were evaluated. Radiological PPFE was observed in 30/118 cases (25%): definite PPFE (PPFE concentrated in the upper lobes, with involvement of lower lobes being less marked) in 12 (10%) and consistent PPFE (PPFE not concentrated in the upper lobes, or PPFE with features of coexistent disease present elsewhere) in 18 (15%). Of these, 12 had late-onset non-infectious pulmonary complications after hematopoietic stem-cell transplantation and/or chemotherapy (LONIPCs), 9 idiopathic PPFE, and 9 other fibrotic ILDs (idiopathic pulmonary fibrosis, IPF; other idiopathic interstitial pneumonias, other IIPs; connective tissue disease-associated ILD, CTD-ILD, and hypersensitivity pneumonia, HP). Radiological PPFE was associated with previous history of pneumothorax, lower body mass index, lower percentage of predicted forced vital capacity (%FVC), higher percentage of predicted diffusion capacity of carbon monoxide, less desaturation on six-minute walk test, and hypercapnia. The median survival time of all study cases was 449 days. Thirty-seven (28%) received LTs: cadaveric in 31 and living-donor lobar in six. Of 93 patients who did not receive LT, 66 (71%) died. Radiological PPFE was marginally associated with better survival after adjustment for age, sex, %FVC, and six-minute walk distance < 250 m (hazard ratio 0.51 [0.25–1.05], p = 0.07). After adjustment for covariates, idiopathic PPFE and LONIPC with radiological PPFE was associated with better survival than fibrotic ILDs without radiological PPFE (hazard ratio 0.38 [0.16–0.90], p = 0.03), and marginally better survival than other fibrotic ILDs with radiological PPFE (hazard ratio, 0.20 [0.04–1.11], p = 0.07). idiopathic PPFE and LONIPC with radiological PPFE has better survival on the wait list for LT than fibrotic ILDs without radiological PPFE, after adjustment for age, sex, %FVC, and six-minute walk distance.

1 May 2020
Verified
Journal Article
Closed access
TCToyofumi Chen-Yoshikawa
Toyofumi Chen-Yoshikawa
TFTakayuki Fukui
Takayuki Fukui
SNShota Nakamura
Shota Nakamura
TIToshinari Ito
Toshinari Ito
YKYuka Kadomatsu
Yuka Kadomatsu
KKKoji Kawaguchi
Koji Kawaguchi

27 June 2019 in International Journal of Computer Assisted Radiology and Surgery
Verified
Journal Article
Open access
PDF file
MNMegumi Nakao
Megumi Nakao
JTJunko Tokuno
Junko Tokuno
TCToyofumi Chen-Yoshikawa
Toyofumi Chen-Yoshikawa
HDHiroshi Date
Hiroshi Date
TMTetsuya Matsuda
Tetsuya Matsuda
To facilitate intraoperative localization of lung nodules, this study used model-based shape matching techniques to analyze the inter-subject three-dimensional surface deformation induced by pneumothorax. Methods: Contrast- enhanced computed tomography (CT) images of the left lungs of 11 live beagle dogs were acquired at two bronchial pressures (14 and 2 cm\(\,\hbox {H}_2\hbox {O}\)). To address shape matching problems for largely deformed lung images with pixel intensity shift, a complete Laplacian-based shape matching solution that optimizes the differential displacement field was introduced.

8 August 2021 in JTCVS Techniques
Verified
Journal Article
Open access
JTJunko Tokuno
Junko Tokuno
TCToyofumi Chen-Yoshikawa
Toyofumi Chen-Yoshikawa
DNDaisuke Nakajima
Daisuke Nakajima
AAAkihiro Aoyama
Akihiro Aoyama
HMHideki Motoyama
Hideki Motoyama
HDHiroshi Date
Hiroshi Date
Virtual-assisted lung mapping (VAL-MAP) is a bronchoscopic marking method of dye application on the surface of the lungs before resecting nonpalpable nodules. However, in some cases, it can be difficult to identify the markings of VAL-MAP on computed tomography and intraoperative thoracoscopy. We developed and assessed the feasibility of indocyanine green VAL-MAP (ICG-VAL-MAP). A historical control trial was conducted to investigate the effectiveness of ICG-VAL-MAP for marking visualization compared with that of VAL-MAP. In ICG-VAL-MAP, instead of indigo carmine, ICG and computed tomography contrast agents were used for dye marking, and near-infrared fluorescence endoscopy was employed to visualize the ICG markings. The other processes in VAL-MAP were carried out. The marking visibility was assessed in 3 grades of easy, faint, or not identifiable. We compared the visibility of the markings on computed tomography images and during thoracoscopic operations between VAL-MAP (567 markings in 147 cases) and ICG-VAL-MAP (142 markings in 63 cases). On the preoperative computed tomography images, ICG-VAL-MAP provided significantly better marking visualization than VAL-MAP (easy/faint/not identifiable = 142/0/0 vs 427/100/30; P < .0001). ICG-VAL-MAP provided significantly better intraoperative markings than VAL-MAP (easy/faint/not identifiable = 141/0/1, respectively, vs 475/50/42, respectively; P < .0001). Regarding complications, pneumothorax occurred in 8 (5.4%) cases of VAL-MAP and zero cases (0%) of ICG-VAL-MAP (P = .12); fever was observed in 7 (5.0%) cases of VAL-MAP and 2 (3.2%) cases of ICG-VAL-MAP (P = .72). ICG-VAL-MAP provided significantly better visibility of markings than VAL-MAP. It might be useful in the resection of nonpalpable small lung lesions.